title: Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica.
abstract: The aim of this study was to analyze the longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica (PMR). Patients diagnosed with PMR were collected retrospectively in two rheumatology departments. In addition to demographic and diagnostic criteria, the chart review included the following information at baseline and at follow-up: doses of prednisone, prescription of calcium, vitamin D and bisphosphonates, bone mass measurement (BMD) and fragility fractures. We analyzed the percentage of patients undergoing BMD and were prescribed a bisphosphonate over the years. We evaluated 158 patients: 117 of them were women, mean age was 73 years, and they had an average follow-up of 4.8 years. 104 patients (66 %) received osteoporosis medication during the first visit, 44 of them were given bisphosphonate. During follow-up, another 30 treatments with bisphosphonate were added (46 % overall) while 37 cases (23 %) received no treatment with calcium or bisphosphonate. BMD was performed in 111 patients (69 %; 53 % of males and 76 % of females). Factors associated with the use of bisphosphonates were female sex (OR 4.4, 95 % CI 4.02-4.86), BMD (OR 2.4, 95 % CI 2.05-2.78) and commencement of treatment after the year 2005 (54 vs 37 %, OR 1.93, 95 % CI 1.60-2.26). No significant differences were found with age, initial doses of prednisone or the hospital. According to recent prevention guidelines, treatment with biphosphonate should have been administered in more than 90 % of patients. Although prophylaxis of glucocorticoid-induced osteoporosis in patients with PMR has increased in the recent years, many patients do not receive prophylaxis with bisphosphonate during the first visit.
authors.affiliation: Department of Rheumatology, Hospital Universitario Gran Canaria Dr. Negrin, Universidad de Las Palmas de Gran Canaria, La Ballena s/n, 35010, Las Palmas, Spain, anarher@gobiernodecanarias.org.
authors.forename: Antonio
authors.initials: A
authors.lastname: Naranjo
authors.forename: Rubén
authors.initials: R
authors.lastname: López
authors.forename: Blanca
authors.initials: B
authors.lastname: García-Magallón
authors.forename: Laura
authors.initials: L
authors.lastname: Cáceres
authors.forename: Félix
authors.initials: F
authors.lastname: Francisco
authors.forename: Mercedes
authors.initials: M
authors.lastname: Jiménez-Palop
authors.forename: Soledad
authors.initials: S
authors.lastname: Ojeda-Bruno
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000517:prevention & control*; D011111:Polymyalgia Rheumatica / Q000188:drug therapy*; D011859:Radiography; D016896:Treatment Outcome
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids
references.citation: Reumatol Clin. 2007 Mar;3 Suppl 1:S3-8
references.pmid: 21794455
references.citation: Arthritis Rheum. 2012 Apr;64(4):943-54
references.pmid: 22389040
references.citation: J Clin Rheumatol. 2009 Jun;15(4):155-60
references.pmid: 19363452
references.citation: N Engl J Med. 2007 Nov 15;357(20):2028-39
references.pmid: 18003959
references.citation: Lancet. 2009 Apr 11;373(9671):1253-63
references.pmid: 19362675
references.citation: J Bone Miner Res. 2004 Jun;19(6):893-9
references.pmid: 15125788
references.citation: Reumatol Clin. 2011 Nov-Dec;7(6):357-79
references.pmid: 22078694
references.citation: Arthritis Rheum. 2001 Jul;44(7):1496-503
references.pmid: 11465699
references.citation: Rheumatology (Oxford). 2010 Jan;49(1):186-90
references.pmid: 19910443
references.citation: Arthritis Rheum. 1999 Nov;42(11):2309-18
references.pmid: 10555025
references.citation: Bone Miner. 1990 Jan;8(1):39-51
references.pmid: 2306553
references.citation: J Clin Rheumatol. 2008 Jun;14(3):153-5
references.pmid: 18525434
references.citation: Ann Rheum Dis. 1979 Oct;38(5):434-9
references.pmid: 518143
references.citation: Ann Rheum Dis. 2002 Jan;61(1):32-6
references.pmid: 11779755
references.citation: Arthritis Rheum. 2003 Nov;48(11):3224-9
references.pmid: 14613287
references.citation: Osteoporos Int. 2011 Jan;22(1):305-15
references.pmid: 20358362
references.citation: Calcif Tissue Int. 2000 Oct;67(4):277-85
references.pmid: 11000340
references.citation: Arthritis Rheum. 1996 Nov;39(11):1791-801
references.pmid: 8912500
references.citation: Arthritis Care Res (Hoboken). 2010 Nov;62(11):1515-26
references.pmid: 20662044
references.citation: QJM. 2008 Apr;101(4):317-23
references.pmid: 18270228
references.citation: N Engl J Med. 1998 Jul 30;339(5):292-9
references.pmid: 9682041
references.citation: J Bone Miner Res. 2000 Jun;15(6):1006-13
references.pmid: 10841169
references.citation: Arthritis Rheum. 2005 Aug;52(8):2485-94
references.pmid: 16052570